Related Experiment Video
Updated: Aug 15, 2026
02:28
Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Outcome measures in psoriatic arthritis
Dafna D Gladman1, Philip J Mease, Gerald Krueger
1University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto, Canada. dafna.gladman@utoronto.ca
The Journal of Rheumatology
|November 3, 2005
Summary
New biologic therapies offer psoriatic arthritis (PsA) hope, but validated outcome measures are needed. This review summarizes OMERACT 7 findings, defining key assessment domains and a research agenda for PsA.
Area of Science:
- Rheumatology
- Dermatology
Background:
- Biologic therapies show promise for psoriatic arthritis (PsA) patients.
- Clinical studies are limited by the absence of validated outcome measures for skin and joint assessment in PsA.
Framework:
- Review of current outcome measures for skin and joint manifestations in PsA.
- Summary of the Psoriatic Arthritis Workshop at OMERACT 7.
- Identification of essential domains for comprehensive PsA patient assessment.
Implementation:
- The Psoriatic Arthritis Workshop at OMERACT 7 convened experts to address outcome measure challenges.
- A consensus was reached on key domains for evaluating PsA patients.
Implications:
- Development of a research agenda to guide the creation and validation of new outcome measures.
- Improved assessment of PsA patients, facilitating more robust clinical trials and therapeutic advancements.
